Literature DB >> 23000598

Development of robust hepatitis C virus genotype 4 subgenomic replicons.

Betty Peng1, Mei Yu, Simin Xu, Yu-Jen Lee, Yang Tian, Huiling Yang, Katie Chan, Hongmei Mo, John McHutchison, William Delaney, Guofeng Cheng.   

Abstract

Despite the prevalence of hepatitis C virus genotype 4, no replicon system is available for study of the genotype. To facilitate discovery and development of reagents against this virus, we synthesized and transcribed a genotype 4a subgenomic replicon and transfected Huh7-Lunet cells with it, which yielded very few colonies. However, when we used a new Huh-7-derived cell line, colony formation increased ∼70-fold. We identified multiple adaptive mutations in the virus's nonstructural 3 or 4A proteins that allowed the cells to maintain stable, genotype 4a luciferase-encoding replicons. Several classes of hepatitis C virus inhibitors had different antiviral effects on genotypes 4a vs 1b. The genotype 4a replicon system we created will aid in the development of treatment regimens for all genotypes of hepatitis C virus.
Copyright © 2013 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23000598     DOI: 10.1053/j.gastro.2012.09.033

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  11 in total

1.  Inhibition of hepatitis C virus replication by GS-6620, a potent C-nucleoside monophosphate prodrug.

Authors:  Joy Y Feng; Guofeng Cheng; Jason Perry; Ona Barauskas; Yili Xu; Martijn Fenaux; Stacey Eng; Neeraj Tirunagari; Betty Peng; Mei Yu; Yang Tian; Yu-Jen Lee; George Stepan; Leanna L Lagpacan; Debi Jin; Magdeleine Hung; Karin S Ku; Bin Han; Kathryn Kitrinos; Michel Perron; Gabriel Birkus; Kelly A Wong; Weidong Zhong; Choung U Kim; Anne Carey; Aesop Cho; Adrian S Ray
Journal:  Antimicrob Agents Chemother       Date:  2014-01-13       Impact factor: 5.191

2.  Hepatitis C virus genotype 5a subgenomic replicons for evaluation of direct-acting antiviral agents.

Authors:  Constance N Wose Kinge; Christine Espiritu; Nishi Prabdial-Sing; Nomathamsaqa Patricia Sithebe; Mohsan Saeed; Charles M Rice
Journal:  Antimicrob Agents Chemother       Date:  2014-06-30       Impact factor: 5.191

3.  Robust and persistent replication of the genotype 6a hepatitis C virus replicon in cell culture.

Authors:  Mei Yu; Betty Peng; Katie Chan; Ruoyu Gong; Huiling Yang; William Delaney; Guofeng Cheng
Journal:  Antimicrob Agents Chemother       Date:  2014-02-18       Impact factor: 5.191

4.  Hepatitis C Virus Genotype 1 to 6 Protease Inhibitor Escape Variants: In Vitro Selection, Fitness, and Resistance Patterns in the Context of the Infectious Viral Life Cycle.

Authors:  Stéphanie B N Serre; Sanne B Jensen; Lubna Ghanem; Daryl G Humes; Santseharay Ramirez; Yi-Ping Li; Henrik Krarup; Jens Bukh; Judith M Gottwein
Journal:  Antimicrob Agents Chemother       Date:  2016-05-23       Impact factor: 5.191

5.  Clinical Resistance to Velpatasvir (GS-5816), a Novel Pan-Genotypic Inhibitor of the Hepatitis C Virus NS5A Protein.

Authors:  Eric J Lawitz; Hadas Dvory-Sobol; Brian P Doehle; Angela S Worth; John McNally; Diana M Brainard; John O Link; Michael D Miller; Hongmei Mo
Journal:  Antimicrob Agents Chemother       Date:  2016-08-22       Impact factor: 5.191

Review 6.  The molecular and structural basis of advanced antiviral therapy for hepatitis C virus infection.

Authors:  Ralf Bartenschlager; Volker Lohmann; Francois Penin
Journal:  Nat Rev Microbiol       Date:  2013-06-10       Impact factor: 60.633

7.  NS5A Sequence Heterogeneity and Mechanisms of Daclatasvir Resistance in Hepatitis C Virus Genotype 4 Infection.

Authors:  Nannan Zhou; Dennis Hernandez; Joseph Ueland; Xiaoyan Yang; Fei Yu; Karen Sims; Philip D Yin; Fiona McPhee
Journal:  J Infect Dis       Date:  2015-07-13       Impact factor: 5.226

Review 8.  Hepatitis C Virus and Antiviral Drug Resistance.

Authors:  Seungtaek Kim; Kwang-Hyub Han; Sang Hoon Ahn
Journal:  Gut Liver       Date:  2016-11-15       Impact factor: 4.519

Review 9.  HCV Replicon Systems: Workhorses of Drug Discovery and Resistance.

Authors:  Shaheen Khan; Shalini Soni; Naga Suresh Veerapu
Journal:  Front Cell Infect Microbiol       Date:  2020-06-30       Impact factor: 5.293

10.  In Vitro Antiviral Activity and Resistance Profile Characterization of the Hepatitis C Virus NS5A Inhibitor Ledipasvir.

Authors:  Guofeng Cheng; Yang Tian; Brian Doehle; Betty Peng; Amoreena Corsa; Yu-Jen Lee; Ruoyu Gong; Mei Yu; Bin Han; Simin Xu; Hadas Dvory-Sobol; Michel Perron; Yili Xu; Hongmei Mo; Nikos Pagratis; John O Link; William Delaney
Journal:  Antimicrob Agents Chemother       Date:  2016-01-11       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.